Prevalence of Polycystic Ovary Syndrome Among Premenopausal Women With Type 2 Diabete

visit the link at the bottom of the page to view the illustrations assciated with this article

“Prevalence of Polycystic Ovary Syndrome Among Premenopausal Women With Type 2 Diabetes ” posted on June 26, 2001

——————————————————————————–

More PCOS Research @ SoulCysters.com
Stariss123#

Prevalence of Polycystic Ovary Syndrome Among Premenopausal Women With Type 2 Diabetes
Heather R. Peppard, BS1, Jennifer Marfori, BS1, Maria J. Iuorno, MD1 and John E. Nestler, MD1,2
1 Division of Endocrinology and Metabolism, Department of Internal Medicine
2 Department of Obstetrics and Gynecology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

ABSTRACT
TOP
ABSTRACT
INTRODUCTION
RESEARCH DESIGN AND METHODS
RESULTS
CONCLUSIONS
References

OBJECTIVE—Women with polycystic ovary syndrome (PCOS) have an increased risk for developing type 2 diabetes. Few studies have assessed women with type 2 diabetes to determine the frequency of PCOS in this population.

RESEARCH DESIGN AND METHODS—To determine the prevalence of PCOS among premenopausal women with type 2 diabetes, we conducted a retrospective cross-sectional prevalence study. We reviewed the medical records of all women seen in the Diabetes Clinic of the Medical College of Virginia Hospitals between January 1995 through February 2000. A diagnosis of PCOS was based on 1) oligomenorrhea, 2) hyperandrogenism (biochemical or clinical), and 3) exclusion of other related disorders.

RESULTS—We reviewed the medical records of 618 women with diabetes and identified 47 women eligible for study. Of the 47 women, 30 consented to an evaluation. Of the 30 women evaluated, 8 were identified as having PCOS (6 women reported a previous PCOS diagnosis and 2 women were newly diagnosed), resulting in a prevalence of 26.7%.

CONCLUSIONS—We concluded that PCOS occurs frequently among premenopausal women with type 2 diabetes.

Abbreviations: PCOS, polycystic ovary syndrome • TSH, thyroid-stimulating hormone

INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
RESEARCH DESIGN AND METHODS
RESULTS
CONCLUSIONS
References

Polycystic ovary syndrome (PCOS) is characterized by chronic anovulation and hyperandrogenism, and affects an estimated 4.6% of U.S. women of reproductive age (1). Women with PCOS are at an increased risk for infertility, preeclampsia, early pregnancy loss, and endometrial cancer. Moreover, because of the association of PCOS with insulin resistance (2), evidence suggests that women with PCOS are at an increased risk for developing type 2 diabetes, dyslipidemia, hypertension, and heart disease (3).

Insulin resistance is also a key factor in the development of type 2 diabetes (4), and since the observation in 1921 by Achard and Thiers (5) of the bearded woman with diabetes, these two disorders have been linked. Several studies have clearly demonstrated that women with PCOS are at high risk for developing type 2 diabetes. Prospective clinical trials have demonstrated a 31–35% prevalence of impaired glucose tolerance and a 7.5–10.0% prevalence of type 2 diabetes in women with PCOS (6,7). It has also been reported that the rate of conversion from impaired glucose tolerance to type 2 diabetes is increased 5- to 10-fold in women with PCOS (6).

However, only one study (8) has examined the association of PCOS with diabetes from the opposite perspective: That is, how prevalent is PCOS among premenopausal women with type 2 diabetes? To address this issue, we conducted a chart review of all women seen in our diabetes clinic over a 5-year period to determine the prevalence of PCOS. Our hypothesis was that PCOS is a highly prevalent and unrecognized entity among women with type 2 diabetes and that the presence of PCOS would be higher in women with type 2 diabetes than in nondiabetic women.

RESEARCH DESIGN AND METHODS
TOP
ABSTRACT
INTRODUCTION
RESEARCH DESIGN AND METHODS
RESULTS
CONCLUSIONS
References

We reviewed the charts of all women seen in the Diabetes Clinic of the Medical College of Virginia Hospitals from 1 January 1995 through 29 February 2000. We identified 618 women, and 51 women met the inclusion criteria of 1) diagnosis of type 2 diabetes and 2) age 18–45 years. Exclusion criteria included 1) postmenopausal state, 2) bilateral oophorectomy, or 3) hysterectomy because these conditions precluded determination of menstrual frequency or circulating androgen levels. Four women were excluded on this basis, leaving 47 women eligible for study.

We attempted to contact all eligible women by telephone and, failing that, by mail. Women who gave verbal consent responded to a telephone questionnaire on reproductive and medical history, number of menstrual periods per year, number of pregnancies and live births, previous birth control, and fertility modalities. Women who reported a history of eight or fewer menses annually were invited for further evaluation on the General Clinical Research Center. At this visit, written informed consent was obtained, and height, weight, and hip-to-waist ratio were recorded. The presence of hirsutism was established using a modified Ferriman-Gallawey score of >6 (9). Serum samples were drawn for total and free testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, thyroid-stimulating hormone (TSH), and prolactin. Women were diagnosed with PCOS using criteria established at the 1990 National Institute of Child Health and Human Development conference on PCOS (10). That is, women were diagnosed as having PCOS if they had 1) oligomenorrhea (eight or fewer menstrual periods annually) and 2) hyperandrogenism (either clinical hirsutism or elevated serum total or free testosterone) and if the diagnoses of hypothyroidism, hyperprolactinemia, and nonclassical adrenal hyperplasia had been excluded (10).

RESULTS
TOP
ABSTRACT
INTRODUCTION
RESEARCH DESIGN AND METHODS
RESULTS
CONCLUSIONS
References

Of the 47 women eligible for study, 15 women could not be contacted and 2 refused to participate. There were 30 women who verbally consented to the telephone questionnaire. Of these women, 22 reported regular monthly menses (i.e., 12 menses per year) and 8 reported a menstrual history of oligomenorrhea (8 or fewer menses annually).

The eight oligomenorrheic women were invited to undergo further evaluation at the General Clinical Research Center. Three women who had been previously diagnosed with PCOS (subjects 6–8 in Table 1) declined further evaluation due to individual travel restrictions. We were able to document biochemical hyperandrogenemia (i.e., elevated serum total or free testosterone concentrations) in the medical records of two of these three women (subjects 6 and 8 in Table 1). The remaining woman (subject 7 in Table 1) who declined further evaluation suffered from virtual amenorrhea and reported a sufficient degree of hirsutism to warrant a presumptive diagnosis of PCOS.

View this table:
[in this window]
[in a new window]
Table 1 — Characteristics of eight women evaluated for PCOS

Of the remaining five women who were evaluated at the General Clinical Research Center, three had been previously diagnosed with PCOS (subjects 1, 2, and 5 in Table 1) and two did not (subjects 3 and 4 in Table 1). All five were determined to be hirsute, and the three women who were not on hormonal therapy demonstrated biochemical hyperandrogenemia (subjects 1, 2, and 5 in Table 1). Results of TSH, prolactin, and 17-hydroxyprogesterone were within normal limits for all five women. Patient characteristics and results of their evaluation are listed in Table 1.
Thus, all eight oligomenorrheic women were found to have PCOS, resulting in a prevalence rate of 26.7% (8 of 30 women).

It is notable that the 8 women with PCOS did not differ from the 22 unaffected women with respect to age, age of onset or duration of diabetes, BMI, or racial distribution (Table 2). As expected, the women with PCOS had a significantly decreased frequency of menstrual periods and decreased fertility in comparison to the unaffected women (Table 2).

View this table:
[in this window]
[in a new window]
Table 2 — Characteristics of the PCOS and non-PCOS diabetic patients

continued…